Triochem Products Limited has submitted its quarterly compliance report to BSE Limited, confirming zero interest payment obligations for the upcoming quarter from April 2026 to June 2026. The report was filed under Regulation 57(4) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Compliance Report Details

The company filed a NIL report dated March 19, 2026, stating that it has not issued any debt securities or non-convertible securities. Consequently, there are no interest payment obligations due for the ensuing quarter.

Corporate Information

Triochem Products Limited operates from its registered office located at 4th Floor, Sambava Chambers, Sir. P. M. Road, Fort, Mumbai, Maharashtra, PIN: 400001. The company trades on BSE Limited under scrip code 512101.

Filing Authority

The compliance report was digitally signed and submitted by Ureca Deolekar, Company Secretary & Compliance Officer, on March 19, 2026. The document reference number is TPL PP 20260321 2026.

Regulatory Context

The filing fulfills the company's obligation under SEBI regulations to report on debt security payment obligations quarterly. Since Triochem Products Limited has not issued any bonds or non-convertible debentures, the NIL report confirms the absence of any related payment obligations for the specified quarter.

Triochem Products Limited has re-submitted its unaudited standalone financial results for the quarter and nine months ended 31st December 2025 to BSE Limited, following regulatory observations regarding a typographical error in the Limited Review Report. The pharmaceutical company corrected the period mentioned in the report from December 31, 2024 to December 31, 2025.

Financial Performance Overview

The company's financial performance for Q3FY26 showed challenging results across key metrics:

For the nine-month period ended December 31, 2025, the company reported a net loss of Rs. 35.50 lakhs compared to a net profit of Rs. 5.17 lakhs in the corresponding period of the previous year.

Regulatory Compliance and Re-submission

BSE Limited had issued a non-compliance notice dated 20th February 2026 under Regulation 33 of SEBI (LODR) Regulations, 2015, highlighting the typographical error in the Limited Review Report. The company acknowledged the error and confirmed that there were no changes in the actual financial results, only the correction of the wrong period mentioned in the auditor's report.

The Board of Directors approved the financial results at its meeting held on Friday, 13th February 2026, with Mr. Ramu S. Deora, Director, serving as the Chairperson of the meeting.

Operational and Strategic Developments

The company operates in a single segment of chemicals and pharmaceuticals. During the period, Triochem Products received shareholder approval on 13th December 2025 for the sale of immovable properties, plant & machinery, and investment property situated in Maharashtra.

The assets have been classified as 'Assets Held for Sale' in accordance with Ind AS 105, with the transaction expected to be completed on or before 31st March 2026. The proceeds are intended for new business ventures and strategic initiatives.

Expense Analysis

The company's expense structure for Q3FY26 included employee benefit expenses of Rs. 14.44 lakhs, other expenditure of Rs. 23.62 lakhs, and depreciation expenses of Rs. 1.36 lakhs, totaling Rs. 39.42 lakhs against total income of Rs. 22.06 lakhs.

The financial results were reviewed by the Audit Committee and approved by the Board of Directors, with statutory auditors Kanu Doshi Associates LLP providing an unqualified review conclusion on the statements.